[1. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19:305-13.10.1200/JCO.2001.19.2.30511208820]Search in Google Scholar
[2. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamouscell cancer of the esophagus. N Engl J Med. 1997; 337: 161-7.10.1056/NEJM1997071733703049219702]Search in Google Scholar
[3. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326:1593-8.10.1056/NEJM1992061132624031584260]Search in Google Scholar
[4. Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radio Graphics. 2009; 29:403-21.10.1148/rg.29208510619325056]Search in Google Scholar
[5. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy- systematic review. Radiology. 2005; 236:841-51.10.1148/radiol.236304104216118165]Search in Google Scholar
[6. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 12:3058-65.10.1200/JCO.2001.19.12.305811408502]Search in Google Scholar
[7. Br cher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg. 2001; 3: 300-9.10.1097/00000658-200103000-00002142124411224616]Search in Google Scholar
[8. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005; 4:1053-9.10.1016/j.ijrobp.2005.03.03315964705]Open DOISearch in Google Scholar
[9. Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009; 73: 136-41.10.1016/j.ijrobp.2008.04.01518538492]Open DOISearch in Google Scholar
[10. Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, et al. Comparison of (18)F-fluorothymidine and (18)Ffluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys. 2010; 15;76:1235-41.10.1016/j.ijrobp.2009.07.168119910143]Open DOISearch in Google Scholar
[11. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005; 77:247-53.10.1016/j.radonc.2005.10.017]Open DOISearch in Google Scholar
[12. Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD, et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim. 2007; 32:166-71.10.1016/j.meddos.2006.12.003]Open DOISearch in Google Scholar
[13. La TH, Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, et al. Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Dis Esophagus. 2010; 23;300-8.10.1111/j.1442-2050.2009.01004.x]Open DOISearch in Google Scholar
[14. Wu VW, Sham JS, Kwong DL. Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer. Br J Radiol. 2004; 77:568-72.10.1259/bjr/19972578]Open DOISearch in Google Scholar
[15. Nutting CM, Bedford JL, Cosgrove VP, Tait DM, Dearnaley DP, Webb S. A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol. 2001; 61:157-63.10.1016/S0167-8140(01)00438-8]Open DOISearch in Google Scholar
[16. Hsu FM, Lee YC, Lee JM, Hsu CH, Lin CC, Tsai YC, et al. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensitymodulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy. Ann Surg Oncol. 2009; 16:1669-77.10.1245/s10434-009-0401-019267157]Open DOISearch in Google Scholar
[17. Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006; 12:5501-8.10.3748/wjg.v12.i34.5501408823317006988]Open DOISearch in Google Scholar
[18. American Joint Committee on Cancer. Esophagus, 6th ed. New York: Springer Verlag. 2002.]Search in Google Scholar
[19. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov: August 9, 2006 http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed 1 August 2009.]Search in Google Scholar
[20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50:122S-50S.10.2967/jnumed.108.057307275524519403881]Open DOISearch in Google Scholar
[21. Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, et al. Predictive value of 18-fluorodeoxy- glucose-positron emission tomography (18FFDG- PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006; 243: 472-8.10.1097/01.sla.0000208430.07050.61144895316552197]Open DOISearch in Google Scholar
[22. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy-Dglucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004; 101:1776-85.10.1002/cncr.2058515386332]Open DOISearch in Google Scholar
[23. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281:1623-7.]Search in Google Scholar
[24. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20:1167-74.10.1200/JCO.2002.20.5.1167]Search in Google Scholar
[25. Bedenne L, Michel P, Bouch_ O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007; 25:1160-8.10.1200/JCO.2005.04.7118]Open DOISearch in Google Scholar
[26. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005; 23:2310-7.10.1200/JCO.2005.00.034]Open DOISearch in Google Scholar
[27. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335:462-7.10.1056/NEJM199608153350702]Search in Google Scholar
[28. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26:1086-92.10.1200/JCO.2007.12.9593]Open DOISearch in Google Scholar
[29. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgeray for resectable cancer of the oesophagus: a randomized controlled phase III trial. Lancet Oncol. 2005; 6:659-68.10.1016/S1470-2045(05)70288-6]Open DOISearch in Google Scholar
[30. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994; 73:1779-84.10.1002/1097-0142(19940401)73:7<1779::AID-CNCR2820730702>3.0.CO;2-T]Open DOISearch in Google Scholar
[31. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992; 16:1104-9.10.1007/BF02067069]Open DOISearch in Google Scholar
[32. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994; 41:391-3.]Search in Google Scholar
[33. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010. 10.023.]Search in Google Scholar
[34. Shi A, Zhu G, Wu H, Yu R, Li F, Xu B. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy. Radiat Oncol. 2010; 5:35.10.1186/1748-717X-5-35]Open DOISearch in Google Scholar
[35. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002; 3:361-8.10.1093/annonc/mdf08111996465]Open DOISearch in Google Scholar